GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » LT-Debt-to-Total-Asset

CERo Therapeutics Holdings (CERo Therapeutics Holdings) LT-Debt-to-Total-Asset : 0.21 (As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CERo Therapeutics Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2022 was 0.21.

CERo Therapeutics Holdings's long-term debt to total assets ratio increased from . 20 (0.00) to Dec. 2022 (0.21). It may suggest that CERo Therapeutics Holdings is progressively becoming more dependent on debt to grow their business.

CERo Therapeutics Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for CERo Therapeutics Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings LT-Debt-to-Total-Asset Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
LT-Debt-to-Total-Asset
0.13 0.21

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
LT-Debt-to-Total-Asset 0.13 0.21

CERo Therapeutics Holdings LT-Debt-to-Total-Asset Calculation

CERo Therapeutics Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=2.345/11.349
=

CERo Therapeutics Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (Q: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2022 )/Total Assets (Q: Dec. 2022 )
=2.345/11.349
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings  (NAS:CERO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CERo Therapeutics Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
Website
https://www.cero.bio
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024